Home | Welcome to Contract Pharma   
Last Updated Wednesday, September 3 2014
Print

Financial Reports: Gilead



By Gil Roth



Published February 5, 2014
Gilead 4Q13

4Q Revenues: $3.1 billion (+21%)

4Q Earnings: $791 million (+4%)

FY Revenues: $11.2 billion (+15%)

FY Earnings: $3.1 billion (+19%)

Comments: Product sales rose 21% in 4Q to $3.0 billion, driven by Stribild (+409% to $204 million), and Complera/Eviplera (+122% to $262 million). Atripla sales rose 2% to $934 million. In FY13, Atripla sales were up 2% to $3.6 billion, while Stribild posted $539 million (+837%) and Complera/Eviplera had $809 million in revenues (+137%). Gilead's cardiovascular franchise posted 24% gains in FY, with Letairis posting $520 million in sales (+27%) and Ranexa adding $449 million (+20%).


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On